ArticleJournal of neurology2026
Disability progression in multiple sclerosis: a latent class analysis of predictors.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4.Journal of neurology · 2026Review
- The Big Picture: 26 Years of Longitudinal Findings About Health Promotion and Quality of Life in Multiple Sclerosis.Healthcare (Basel, Switzerland) · 2026Review
- Predictors of secondary progressive multiple sclerosis in a real word retrospective cohort: the role of clinical factors and disease-modifying therapy patterns.Acta neurologica Belgica · 2026Article
- Targeting pyruvate kinase M2 (PKM2) reduces T cell pathogenicity in multiple sclerosis.EBioMedicine · 2026Article
- Multiple sclerosis as an asynchronous neuroinflammatory system.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMultiple sclerosis (MS) is a heterogeneous disease with highly variable long-term outcomes. We aimed to identify patterns of disability progression and their determinants to improve individualized risk assessment and support clinical decision-making.
methodsWe applied latent class trajectory modeling to Expanded Disability Status Scale (EDSS) data from 3163 newly diagnosed relapsing-onset MS cases in the Swedish Epidemiological Investigation of MS (2005-2019). Baseline demographics, clinical, and lifestyle data were collected at diagnosis, and participants were followed through the Swedish MS registry. Multivariate logistic regression was used to examine associations between baseline characteristics and trajectory group membership. Kaplan-Meier analysis estimated time to confirmed disability worsening, EDSS 3 and EDSS 4 across trajectory groups.
resultsSeven distinct EDSS trajectories were identified. Group 4 (n = 1149) was the most common and characterized by stable, low disability. Groups 5-7 showed steadily increasing disability and were categorized as unfavorable (n = 662). In multivariate models, older age at diagnosis, longer baseline disease duration, higher baseline EDSS score, more frequent early relapses, poor cognitive performance, and autoimmune comorbidities were associated with unfavorable progression. Among lifestyle factors, obesity, smoking, and low sun exposure were linked to worse outcomes, while high physical activity decreased the odds of unfavorable progression. No significant association was observed for baseline vitamin D levels. Time to confirmed disability progression outcomes differed substantially across trajectory groups. DISCUSSION: Early clinical and lifestyle factors were associated with long-term outcomes. These findings illustrate the heterogeneity of MS progression and support further investigation of early modifiable factors influencing long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.